Back to news

Amgen Gains as Investors Appear to Lean on Pipeline and Regulatory Momentum

Investivoq PriceTracker

Amgen (AMGN) is up 3.1% today. Here is some analysis on what might have caused this price movement.

Analysis: A clear same-day catalyst is not obvious, so this could be because investors are leaning on Amgen’s broader pipeline and recent regulatory momentum. Sentiment may also be getting support from the company’s obesity program and from the absence of any newly surfaced operational disruption in the latest public materials reviewed.

Details:

  • Amgen’s most recent quarterly materials said three Phase 3 studies of MariTide in people with type 2 diabetes were expected to start in 2026, keeping attention on a major long-term growth opportunity.
  • Amgen also highlighted continued investment in manufacturing capacity, signaling preparation for future product launches and portfolio expansion.
  • The company received a European Union authorization in July 2026 for Jascayd, adding a fresh regulatory win to the story around its newer medicines.
  • Public SEC materials reviewed did not show a new October filing tied to earnings, guidance, or another obvious event that alone would neatly explain a one-day jump, which makes the move look at least partly sentiment-driven.

    • Sources:

    Amgen, SEC, European Medicines Agency

    Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

    $AMGN Insider Trading Activity

    AMGN Insider Trades

    $AMGN insiders have traded $AMGN stock on the open market 7 times in the past 6 months. Of those trades, 0 have been purchases and 7 have been sales.

    Here’s a breakdown of recent trading of $AMGN stock by insiders over the last 6 months:

    • NANCY A. GRYGIEL (SVP & CCO) has made 0 purchases and 3 sales selling 4,207 shares for an estimated $1,594,866.
    • DEREK MILLER (SVP, Human Resources) has made 0 purchases and 2 sales selling 3,890 shares for an estimated $1,565,897.
    • RACHNA KHOSLA (SVP, Business Development) has made 0 purchases and 2 sales selling 3,252 shares for an estimated $1,346,498.

    To track insider transactions, check out Investivoq's insider trading dashboard. You can access data on insider stock transactions through the Investivoq API insider transaction endpoint.

    Investivoq Alerts
    Receive AMGN Data Alerts
    Get market-moving data, filings, and signals for AMGN in real time.
    Sign Up

    $AMGN Hedge Fund Activity

    We have seen 1,397 institutional investors add shares of $AMGN stock to their portfolio, and 1,332 decrease their positions in their most recent quarter.

    Here are some of the largest recent moves:

    • SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 15,034,038 shares (+inf%) to their portfolio in Q2 2026, for an estimated $5,444,125,840
    • INVESCO LTD. added 11,748,721 shares (+257.0%) to their portfolio in Q2 2026, for an estimated $4,254,446,848
    • CAPITAL INTERNATIONAL INVESTORS removed 5,453,497 shares (-76.6%) from their portfolio in Q2 2026, for an estimated $1,974,820,333
    • JPMORGAN CHASE & CO added 3,588,484 shares (+inf%) to their portfolio in Q2 2026, for an estimated $1,299,461,826
    • WELLINGTON MANAGEMENT GROUP LLP added 2,514,254 shares (+1102.7%) to their portfolio in Q2 2026, for an estimated $910,461,658
    • BLACKROCK, INC. added 2,261,544 shares (+4.8%) to their portfolio in Q2 2026, for an estimated $818,950,313
    • CHARLES SCHWAB INVESTMENT MANAGEMENT INC added 2,260,652 shares (+17.7%) to their portfolio in Q2 2026, for an estimated $818,627,302

    To track hedge funds' stock portfolios, check out Investivoq's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Investivoq API 13F endpoint.

    $AMGN Congressional Stock Trading

    Members of Congress have traded $AMGN stock 6 times in the past 6 months. Of those trades, 2 have been purchases and 4 have been sales.

    Here’s a breakdown of recent trading of $AMGN stock by members of Congress over the last 6 months:

    • REPRESENTATIVE DAVID TAYLOR has traded it 4 times. They made 2 purchases worth up to $30,000 on 09/22, 06/05 and 2 sales worth up to $30,000 on 08/26.
    • SENATOR SHELDON WHITEHOUSE sold up to $15,000 on 08/12.
    • REPRESENTATIVE MARIA ELVIRA SALAZAR sold up to $50,000 on 04/17.

    To track congressional stock trading, check out Investivoq's congressional trading dashboard. You can access data on congressional stock trades through the Investivoq API Congress trades endpoint.

    $AMGN Price Targets

    Multiple analysts have issued price targets for $AMGN recently. We have seen 7 analysts offer price targets for $AMGN in the last 6 months, with a median target of $340.0.

    Here are some recent targets:

    • Terence Flynn from Morgan Stanley set a target price of $333.0 on 07/08/2026
    • Gregory Renza from Truist Securities set a target price of $340.0 on 07/07/2026
    • Carter Gould from Cantor Fitzgerald set a target price of $350.0 on 07/06/2026
    • Salim Syed from Mizuho set a target price of $303.0 on 06/16/2026
    • David Amsellem from Piper Sandler set a target price of $427.0 on 05/14/2026
    • Vamil Divan from Guggenheim set a target price of $340.0 on 05/04/2026
    • Gary Nachman from Canaccord Genuity set a target price of $366.0 on 04/21/2026

    This article is not financial advice. See Investivoq's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.